Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Vaxil Bio ( (TSE:VXL) ) has issued an update.
Vaxil Bio Ltd. announced the mutual termination of its definitive agreement with Green Data Center Real Estate Inc. This move will see Green Data Centers repay a loan from Vaxil by July 2025 and issue shares worth $50,000 to Vaxil. Despite this, Vaxil remains committed to exploring other strategic options to maximize shareholder value, including the further development of its existing assets.
More about Vaxil Bio
Vaxil Bio is an Israeli immunotherapy biotech company focusing on innovative treatments targeting cancer markers and infectious diseases. Their lead product, ImMucin™, has completed a Phase 1/2 clinical trial for multiple myeloma and has received orphan drug status from both the FDA and EMA.
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$1.1M
Find detailed analytics on VXL stock on TipRanks’ Stock Analysis page.
